当前位置: 首页 > 期刊 > 《中国当代医药》 > 2018年第27期
编号:13275223
抗抑郁药物相关心血管风险的研究进展(5)
http://www.100md.com 2018年9月25日 《中国当代医药》 2018年第27期
     [27]Krahn LE,Hanson CA,Pileggi TS,et al.Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia[J].J Clin Psychiatry,2001,62(2):108-110.

    [28]Service JA,Waring WS.QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone[J].Clin Toxicol(Phila),2008,46(1):71-73.

    [29]Kemp AH,Quintana DS,Gray MA,et al.Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis[J].Biol Psychiatry,2010,67(11):1067-1074.

    [30]Terhardt J,Lederbogen F,Feuerhack A,et al.Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine[J].Clin Neuropharmacol,2013,36(6):198-202.

    [31]Rajpurohit N,Aryal SR,Khan MA,et al.Propafenone associated severe central nervous system and cardiovascular toxicity due to mirtazapine:a case of severe drug interaction[J].S D Med,2014,67(4):137-139.

    [32]Sheline YI,Freedland KE,Carney RM.How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease?[J].Am J Med,1997,102(1):54-59.

    (收稿日期:2018-04-23 本文編辑:闫 佩), 百拇医药(王龙飞 龚山 余国龙)
上一页1 2 3 4 5